Author:
Park Robin,Abushalha Kamelah,Saeed Anwaar
Publisher
Springer International Publishing
Reference77 articles.
1. Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):92. https://doi.org/10.1186/s13045-019-0779-5
2. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. https://doi.org/10.3389/fphar.2017.00561
3. American Cancer Society: Stomach Cancer Survival Rates. https://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html. Accessed 7 Feb 2020
4. American Cancer Society: Survival Rates for Esophageal Cancer. https://www.cancer.org/cancer/esophagus-cancer/detection-diagnosis-staging/survival-rates.html. Accessed 7 Feb 2020
5. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930–2940. https://doi.org/10.1172/JCI91190